

SSD Biologia Integrata Tumori Rari

Elenco pubblicazioni 2021-2023

- 1 - Minna E, Devecchi A, Pistore F, Paolini B, Mauro G, Penso Da, Pagliardini S, Busico A, Pruneri G, De Cecco L, Borrello Mg, Sensi M, Greco A. Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors. *Frontiers In Endocrinology* 2023;14:1267499
- 2 - Cumbo C, Orsini P, Anelli L, Zagaria A, Iannò Mf, De Cecco L, Minervini Cf, Cocco N, Tota G, Parciante E, Conserva Mr, Redavid I, Tarantini F, Minervini A, Carluccio P, De Grassi A, Pierrì Cl, Specchia G, Musto P, Albano F. Case report: biallelic DNMT3A mutations in acute myeloid leukemia. *Frontiers In Oncology* 2023;13:1205220
- 3 - Chiodoni C, Sangaletti S, Lecchi M, Ciniselli Cm, Cancila V, Tripodi I, Ratti C, Talarico G, Bricch S, De Cecco L, Baili P, Truffi M, Sottotetti F, Piccotti F, Tripodo C, Pruneri G, Triulzi T, Corsi F, Cappelletti V, Di Cosimo S, Verderio P, Colombo Mp. A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer. *Esmo Open* 2023;8:101590
- 4 - Corti A, De Cecco L, Cavalieri S, Lenoci D, Pistore F, Calareso G, Mattavelli D, De Graaf P, Leemans Cr, Brakenhoff Rh, Ravanelli M, Poli T, Licitra L, Corino V, Mainardi L. MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures. *Biomarker Research* 2023;11:69
- 5 - Minnai F, Noci S, Mangano N, De Cecco L, Meazza C, Terenziani M, Massimino M, Colombo F. A pilot exome sequencing study suggests that germline variants influence methotrexate-induced toxicities in pediatric patients with localized osteosarcoma. *Pediatric Blood & Cancer* 2023;70:e30501
- 6 - Massimino M, Vennarini S, Buttarelli Fr, Antonelli M, Colombo F, Minasi S, Pecori E, Ferroli P, Giussani C, Schiariti M, Schiavello E, Biassoni V, Erbetta A, Chiapparini L, Nigro O, Boschetti L, Gianni F, Miele E, Modena P, De Cecco L, Pollo B, Barretta F. Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles. *Journal Of Neuro-oncology* 2023;163:577-586
- 7 - Forlani L, De Cecco L, Simeon V, Paolini B, Bagnoli M, Cecere Sc, Spina A, Citeroni E, Bignotti E, Lorusso D, Arenare L, Russo D, De Angelis C, Ardighieri L, Scognamiglio G, Del Sesto M, Tognon G, Califano D, Schettino C, Chiodini P, Perrone F, Mezzanzanica D, Pignata S, Tomassetti A. Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial. *Journal Of Experimental & Clinical Cancer Research* 2023;42:83
- 8 - Cioni B, Ratti S, Piva A, Tripodi I, Milani M, Menichetti F, Langella T, Botti L, De Cecco L, Chiodoni C, Lecis D, Colombo Mp. JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer. *Molecular Cancer Research* 2023;21:614-627
- 9 - Ghislanzoni S, Sarcinelli Gm, Bresci A, Manetti F, Polli D, Tomassetti A, Radice Mt, Bongarzone I. Reduced sulfatide content in deferoxamine-induced senescent HepG2 cells. *International Journal Of Biochemistry & Cell Biology* 2023;159:106419
- 10 - Petrelli A, Rizzolio S, Pietrantonio F, Bellomo Se, Benelli M, De Cecco L, Romagnoli D, Berrino E, Orrù C, Ribisi S, Moya Rull D, Migliore C, Conticelli D, Maina Im, Puliga E, Serra V, Pellegrino B, Llop Guevara A, Musolino A, Siena S, Sartore Bianchi A, Prisciandaro M, Morano F, Antista M, Fumagalli U, De Manzoni G, Degiuli M, Baiocchi GI, Amisano Mf, Ferrero A, Marchiò C, Corso S, Giordano S. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. *Cancer Research* 2023;83:1699-1710

- 11 - Schiavello E, Biassoni V, Gattuso G, Podda M, Chiaravalli S, Barretta F, Antonelli M, De Cecco L, Pecori E, Gandola L, Massimino M. A homogeneous treatment for non-DIPG diffuse midline glioma. *Tumori Journal* 2023;109:269-275
- 12 - Pezzotta A, Brioschi L, Carbone S, Mazzoleni B, Bontempi V, Monastra F, Mauri L, Marozzi A, Mione M, Pistocchi A, Viani P. Combined Inhibition of Hedgehog and HDAC6: In Vitro and In Vivo Studies Reveal a New Role for Lysosomal Stress in Reducing Glioblastoma Cell Viability. *International Journal Of Molecular Sciences* 2023;24:
- 13 - Licata Ag, Ciniselli Cm, Sorrentino L, Micali A, Daidone Mg, Guaglio M, Gariboldi M, Verderio P, De Cecco L, Cosimelli M. Peritoneal fluid COVID-19 testing in patients with a negative nasopharyngeal swab: prospective study. *British Journal Of Surgery* 2023;110:504-505
- 14 - Barcellini A, Charalampopoulou A, De Cecco L, Fodor A, Rabaiotti E, Candotti G, Secondino S, Facchetti A, Locati Ld, Pignata S, Orlandi E, Mangili G. Ovarian Cancer Radiosensitivity: What Have We Understood So Far? *Life-basel* 2023;13:6
- 15 - Bernardo G, Le Noci V, Ottaviano E, De Cecco L, Camisaschi C, Guglielmetti S, Di Modica M, Gargari G, Bianchi F, Indino S, Sartori P, Borghi E, Sommariva M, Tagliabue E, Triulzi T, Sfondrini L. Reduction of *Staphylococcus epidermidis* in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness. *Cancer Letters* 2023;555:216041
- 16 - Bagnoli M, Nicoletti R, Valitutti M, Rizzo A, Napoli A, Montalvão De Azevedo R, Tomassetti A, Mezzanzanica D. Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer. *Frontiers In Oncology* 2022;12:923508
- 17 - Mazzoni M, Todoerti K, Agnelli L, Minna E, Pagliardini S, Di Marco T, Borrello Mg, Neri A, Greco A. Transcriptomic landscape of TIMP3 oncosuppressor activity in thyroid carcinoma. *Cancer Cell International* 2022;22:400
- 18 - Indino S, Borzi C, Moscheni C, Sartori P, De Cecco L, Bernardo G, Le Noci V, Arnaboldi F, Triulzi T, Sozzi G, Tagliabue E, Sfondrini L, Gagliano N, Moro M, Sommariva M. The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles. *International Journal Of Molecular Sciences* 2022;23:232415802
- 19 - Corno C, D'arcy P, Bagnoli M, Paolini B, Costantino M, Carenini N, Corna E, Alberti P, Mezzanzanica D, Colombo D, Linder S, Arrighetti N, Perego P. The deubiquitinase USP8 regulates ovarian cancer cell response to cisplatin by suppressing apoptosis. *Frontiers In Cell And Developmental Biology* 2022;10:1055067
- 20 - Le Noci V, Bernardo G, Manenti G, Infante G, Khaleghi Hashemian D, Minoli L, Canesi S, Bianchi F, Triulzi T, Arioli S, De Cecco L, Guglielmetti S, Ambrogi F, Recordati C, Gagliano N, Tagliabue E, Sommariva M, Sfondrini L. Live or Heat-Killed *Lactobacillus rhamnosus* Aerosolization Decreases Adenomatous Lung Cancer Development in a Mouse Carcinogen-Induced Tumor Model. *International Journal Of Molecular Sciences* 2022;23:232112748
- 21 - Triulzi T, Regondi V, Venturelli E, Gasparini P, Ghirelli C, Groppelli J, Di Modica M, Bianchi F, De Cecco L, Sfondrini L, Tagliabue E. HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer. *Cancers* 2022;14:14225650
- 22 - Casanova M, Pontis F, Ghidotti P, Petraroia I, Venturini Lv, Bergamaschi L, Chiaravalli S, De Cecco L, Massimino M, Sozzi G, Ferrari A, Fortunato O, Gasparini P. MiR-223 Exclusively Impairs In Vitro Tumor Growth through IGF1R Modulation in Rhabdomyosarcoma of Adolescents and Young Adults. *International Journal Of Molecular Sciences* 2022;23:232213989
- 23 - Ciceri S, Carenzo A, Iannó Mf, Bertolotti A, Morosi C, Luksch R, Spreafico F, Collini P, Radice P, Massimino M, De Cecco L, Perotti D. Gene expression-based dissection of inter-histotypes,

intra-histotype and intra-tumor heterogeneity in pediatric tumors. *Scientific Reports* 2022;12:17837

- 24 - Zeng Pyf, Cecchini Mj, Barrett Jw, Shammass Toma M, De Cecco L, Serafini Ms, Cavalieri S, Licitra L, Hoebbers F, Brakenhoff Rh, Leemans Cr, Scheckenbach K, Poli T, Wang X, Liu X, Laxague F, Prisman E, Poh C, Bose P, Dort Jc, Shaikh Mh, Ryan Seb, Dawson A, Khan Mi, Howlett Cj, Stecho W, Plantinga P, Daniela Da Silva S, Hier M, Khan H, Macneil D, Mendez A, Yoo J, Fung K, Lang P, Winqvist E, Palma Da, Ziai H, Amelio Al, Li Ss, Boutros Pc, Mymryk Js, Nichols Ac. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. *Ebiomedicine* 2022;86:104373
- 25 - Gargiuli C, De Cecco L, Mariancini A, Iannò Mf, Micali A, Mancinelli E, Boeri M, Sozzi G, Dugo M, Sensi M. A Cross-Comparison of High-Throughput Platforms for Circulating MicroRNA Quantification, Agreement in Risk Classification, and Biomarker Discovery in Non-Small Cell Lung Cancer. *Frontiers In Oncology* 2022;12:911613
- 26 - Iannò Mf, Biassoni V, Schiavello E, Carezzo A, Boschetti L, Gandola L, Diletto B, Marchesi E, Vegetti C, Molla A, Kramm Cm, Van Vuurden Dg, Gasparini P, Gianni F, Giangaspero F, Modena P, Bison B, Anichini A, Vennarini S, Pignoli E, Massimino M, De Cecco L. A microRNA Prognostic Signature in Patients with Diffuse Intrinsic Pontine Gliomas through Non-Invasive Liquid Biopsy. *Cancers* 2022;14:14174307
- 27 - Fabbi M, Costa D, Russo D, Arenare L, Gaggero G, Signoriello S, Scambia G, Pisano C, Colombo N, Losito Ns, Filaci G, Spina A, Califano D, Scognamiglio G, Gadducci A, Mezzanzanica D, Bagnoli M, Ferrini S, Canzonieri V, Chiodini P, Perrone F, Pignata S. Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab. *Diagnostics* 2022;12:12092118
- 28 - Capoluongo Ed, Pellegrino B, Arenare L, Califano D, Scambia G, Beltrame L, Serra V, Scaglione Gl, Spina A, Cecere Sc, De Cecio R, Normanno N, Colombo N, Lorusso D, Russo D, Nardelli C, D'incalci M, Llop Guevara A, Pisano C, Baldassarre G, Mezzanzanica D, Artioli G, Setaro M, Tasca G, Roma C, Campanini N, Cinieri S, Sergi A, Musolino A, Perrone F, Chiodini P, Marchini S, Pignata S. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial. *Esmo Open* 2022;7:100585
- 29 - Cavalieri S, Serafini Ms, Carezzo A, Canevari S, Lenoci D, Pistore F, Miceli R, Vecchio S, Ferrari D, Moro C, Sponghini A, Caldara A, Rocca Mc, Secondino S, Moretti G, Denaro N, Caponigro F, Vaccher E, Rinaldi G, Ferraù F, Bossi P, Licitra L, De Cecco L. An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer. *Cells* 2022;11:
- 30 - Distefano R, Tomasello L, Rampioni Vinciguerra Gl, Gasparini P, Xiang Y, Bagnoli M, Marceca Gp, Fadda P, Laganà A, Acunzo M, Ma Q, Nigita G, Croce Cm. Pan-Cancer Analysis of Canonical and Modified miRNAs Enhances the Resolution of the Functional miRNAome in Cancer. *Cancer Research* 2022;82:3687-3700
- 31 - Vergani E, Busico A, Dugo M, Devecchi A, Valeri B, Cossa M, Di Guardo L, De Cecco L, Feltrin E, Valle G, Deho P, Frigerio S, Lalli L, Gallino G, Del Vecchio M, Santinami M, Pruneri G, Tamborini E, Rivoltini L, Sensi M, Vallacchi V, Rodolfo M. Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. *Journal Of Investigative Dermatology* 2022;142:3030-3040.e5
- 32 - Minna E, Romeo P, Dugo M, De Cecco L, Aiello A, Pistore F, Carezzo A, Greco A, Borrello Mg. Medullary Thyroid Carcinoma Mutational Spectrum Update and Signaling-Type Inference by Transcriptional Profiles: Literature Meta-Analysis and Study of Tumor Samples. *Cancers* 2022;14:14081951
- 33 - Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im Yh, Bianchi Gv, Galbardi B, Dugo M, De Cecco L, Tseng Lm, Liu Mc, Bermejo B, Semiglazov V, Viale G, De La Haba Rodriguez J, Oh

- Dy, Poirier B, Valagussa P, Gianni L, Tagliabue E. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. *Molecular Oncology* 2022;16:2355-2366
- 34 - Schettino C, Musacchio L, Bartoletti M, Chiodini P, Arenare L, Baldassarre G, Califano D, Capoluongo E, Costi Mp, D'incalci M, Marchini S, Mezzanzanica D, Normanno N, Scala S, Greggi S, Perrone F, Pignata S. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. *International Journal Of Gynecological Cancer* 2022;32:799-803
- 35 - Tomassetti A. Editorial to the Special Issue "Activations of Cadherin Signaling in Cancer". *International Journal Of Molecular Sciences* 2022;23:
- 36 - Carenzo A, Pistore F, Serafini Ms, Lenoci D, Licata Ag, De Cecco L. hacksig: a unified and tidy R framework to easily compute gene expression signature scores. *Bioinformatics* 2022;38:2940-2942
- 37 - Ditto A, De Cecco L, Paolini B, Alberti P, Martinelli F, Leone Roberti Maggiore U, Bogani G, Chiodini P, Pignata S, Tomassetti A, Raspagliesi F, Mezzanzanica D, Bagnoli M. Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. *European Journal Of Cancer* 2022;161:55-63
- 38 - Pizzamiglio S, Cosentino G, Ciniselli Cm, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SI, Rimm DI, Gombos A, Daidone Mg, Verderio P, Tagliabue E, Di Cosimo S, Iorio Mv. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. *Cancer Medicine* 2022;11:332-339
- 39 - Locati Ld, Serafini Ms, Carenzo A, Canevari S, Perrone F, Orlandi E, Delbue S, Cavalieri S, Berzeri G, Pichiecchio A, Licitra Lf, Marchioni E, De Cecco L. Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report. *Frontiers In Oncology* 2022;11:799453
- 40 - Lenoci D, Carenzo A, Cavalieri S, Pistore F, Serafini Ms, Bossi P, Schmitz S, Machiels Jp, Licitra Lf, De Cecco L. Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials. *Oral Oncology* 2022;126:105756
- 41 - Silvestri M, Dugo M, Vismara M, De Cecco L, Lanzoni D, Vingiani A, Folli S, De Santis Mc, De Braud F, Pruneri G, Di Cosimo S, Cappelletti V. Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. *Scientific Reports* 2022;12:1470
- 42 - Pupa Sm, Ligorio F, Cancila V, Franceschini A, Tripodo C, Vernieri C, Castagnoli L. Her2 signaling and breast cancer stem cells: The bridge behind her2-positive breast cancer aggressiveness and therapy refractoriness. *Cancers* 2021;13:
- 43 - Mazzoni M, Mauro G, Minoli L, Cleris L, Anania Mc, Di Marco T, Minna E, Pagliardini S, Rizzetti Mg, Manenti G, Borrello Mg, Scanziani E, Greco A. Senescent thyrocytes, similarly to thyroid tumor cells, elicit m2-like macrophage polarization in vivo. *Biology* 2021;10:985
- 44 - Ciceri S, MontalvÃo De Azevedo R, Tajbakhsh A, Bertolotti A, Spagnuolo Rd, Boschetti L, Capasso M, D'angelo P, Serra A, Diomedi Camassei F, Meli M, Nantron M, Quarello P, Buccoliero Am, Tamburini A, Ciniselli Cm, Verderio P, Collini P, Radice P, Spreafico F, Perotti D. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse. *Cancer Gene Therapy* 2021;28:1016-1024

- 45 - Bonaldi E, Gargiuli C, De Cecco L, Micali A, Rizzetti Mg, Greco A, Borrello Mg, Minna E. Braf inhibitors induce feedback activation of ras pathway in thyroid cancer cells. *International Journal Of Molecular Sciences* 2021;22:
- 46 - Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi Ca, Griguolo G, Marra A, Randon G, Rea Cg, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, De Braud F. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET). *Clinical Cancer Research* 2021;27:3443-3455
- 47 - De Sá Pereira Bm, MontalvÃO De Azevedo R, Da Silva Guerra Jv, Faria Pa, Soares Lima Sc, De Camargo B, Maschietto M. Non-coding RNAs in Wilms' tumor: biological function, mechanism, and clinical implications. *Journal Of Molecular Medicine-jmm* 2021;99:1043-1055
- 48 - Marceca Gp, Distefano R, Tomasello L, Lagana A, Russo F, Calore F, Romano G, Bagnoli M, Gasparini P, Ferro A, Acunzo M, Ma Q, Croce Cm, Nigita G. MiREDiBase, a manually curated database of validated and putative editing events in microRNAs. *Scientific Data* 2021;8:199
- 49 - Ligorio F, Zambelli L, Bottiglieri A, Castagnoli L, Zattarin E, Lobefaro R, Ottini A, Vingiani A, Pupa Sm, Bianchi Gv, Capri G, Pruneri G, De Braud F, Vernieri C. Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. *Therapeutic Advances In Medical Oncology* 2021;13:17588359211006900
- 50 - De Cecco L, Bagnoli M, Chiodini P, Pignata S, Mezzanzanica D. Prognostic evidence of the mirna-based ovarian cancer signature mirovar in independent datasets. *Cancers* 2021;13:
- 51 - Ligorio F, Pellegrini I, Castagnoli L, Vingiani A, Lobefaro R, Zattarin E, Santamaria M, Pupa Sm, Pruneri G, De Braud F, Vernieri C. Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. *Cancer Letters* 2021;511:77-87
- 52 - Rizzo A, Satta A, Garrone G, Cavalleri A, Napoli A, Raspagliesi F, Figini M, De Cecco L, Iorio E, Tomassetti A, Mezzanzanica D, Bagnoli M. Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells. *Journal Of Experimental & Clinical Cancer Research* 2021;40:5